Evidence map›Paper›PMID 31360198›Full record

ArticleArchives of medical science : AMS2019

Microarray gene profiling analysis of glioblastoma cell line U87 reveals suppression of the

Zichuan Wang, Nan Chen, Jin Yang, Qingzhong Wang, Aimin Li

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zichuan WangCollege of Basic Medicine, Nanjing University of Chinese Medicine, Jiangsu, China.
Nan ChenCollege of Basic Medicine, Nanjing University of Chinese Medicine, Jiangsu, China.
Jin YangCollege of Basic Medicine, Nanjing University of Chinese Medicine, Jiangsu, China.
Qingzhong WangDepartment of Neurosurgery, People's Hospital of Guanyun County, Jiangsu, China.
Aimin LiDepartment of Neurosurgery, First People's Hospital of Lianyungang, Jiangsu, China.
Nanjing University of Chinese Medicine · CNThe First People’s Hospital of Lianyungang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA recent study showed that a combination of Y15 (a FAK autophosphorylation inhibitor) with temozolomide (TMZ) treatment was effective in glioblastoma (GBM) therapy. In this study, we further investigated the pathways and genes that are differentially expressed in Y15 and TMZ treated U87 cells via bioinformatics analysis. MATERIAL AND

methodsThe microarray gene profiling analysis screened out genes with differential expression in U87 cells treated with TMZ and Y15. Gene set enrichment analysis (GSEA) identified the key GO terms and KEGG pathways in TMZ + Y15 treated U87 cells. The functional partner genes of TMZ were predicted by the STICH database.

resultsThe FA pathway was suppressed in U87 cells after treatment with TMZ and Y15. Genes involved in this pathway, including

conclusionsThe FA pathway and

Indexed as

FANCD2Fanconi anemia pathwaygene set enrichment analysisglioblastomatemozolomideY15

Identifiers

PMID31360198
PMCPMC6657253
OpenAlexW2950048319

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.